Literature DB >> 17617630

B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity.

Koichi Yanaba1, Yasuhito Hamaguchi, Guglielmo M Venturi, Douglas A Steeber, E William St Clair, Thomas F Tedder.   

Abstract

Rheumatoid arthritis is a systemic autoimmune disease. B cells are likely to play a critical role in arthritis pathogenesis, although it is unclear whether they are necessary for disease induction, autoantibody production, or disease progression. To assess the role of B cells in inflammatory arthritis, B cells were depleted using mouse anti-mouse CD20 mAbs in a mouse model of collagen-induced arthritis. CD20 mAbs effectively depleted mature B cells from adult DBA-1 mice. When B cells were depleted using CD20 mAbs before collagen immunization, there was a delay in disease onset and autoantibody production, with significantly diminished severity of arthritis both clinically and histologically. B cell depletion further delayed disease onset if initiated before, as well as after, collagen immunization. However, in both cases, the eventual reappearance of peripheral B cells triggered autoantibody production and the subsequent development of arthritis in collagen-sensitized mice. By contrast, B cell depletion after collagen immunizations did not have a significant effect on arthritis progression or severity. Thus, disease symptoms were only induced when peripheral B cells and their autoantibody products were present in collagen-immunized mice, documenting a critical role for B cells during the elicitation phase of collagen-induced arthritis. These studies suggest that B cell depletion strategies will be most effective when initiated early in the development of inflammatory arthritis, with sustained B cell depletion required to inhibit the production of isotype-switched pathogenic Abs and the evolution of joint inflammation and destruction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617630     DOI: 10.4049/jimmunol.179.2.1369

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

1.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

2.  B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis.

Authors:  Keith M Hamel; Yanxia Cao; Susan Ashaye; Yumei Wang; Robert Dunn; Marilyn R Kehry; Tibor T Glant; Alison Finnegan
Journal:  J Immunol       Date:  2011-09-23       Impact factor: 5.422

3.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

4.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

5.  IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Yoshihide Asano; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  Killer B lymphocytes: the evidence and the potential.

Authors:  Steven K Lundy
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

7.  B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis.

Authors:  Susan A Olalekan; Yanxia Cao; Keith M Hamel; Alison Finnegan
Journal:  Eur J Immunol       Date:  2015-02-11       Impact factor: 5.532

Review 8.  Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Authors:  Ronald P Taylor; Margaret A Lindorfer
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

9.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

10.  CD19 expression in B cells regulates atopic dermatitis in a mouse model.

Authors:  Koichi Yanaba; Masahiro Kamata; Yoshihide Asano; Yayoi Tada; Makoto Sugaya; Takafumi Kadono; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2013-04-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.